JAKARTA — The discussion surrounding breast cancer prevention and hereditary risks has taken center stage in modern oncology, as medical professionals increasingly emphasize the critical balance between genetic awareness and psychological preparedness. While a family history of breast cancer remains one of the most reliable indicators for assessing an individual’s susceptibility to the disease, leading oncologists are urging the public to exercise caution. Experts warn against undergoing genetic testing impulsively without a comprehensive understanding of the underlying medical benefits, the limitations of the technology, and the profound emotional and medical consequences associated with the results.
The modern understanding of hereditary breast cancer largely revolves around specific genetic mutations that pass from generation to generation. Among the most widely researched and clinically significant are the BRCA1 and BRCA2 genes. According to Dr. Jeffry Beta Tenggara, Sp.PD-KHOM, a specialist in internal medicine and a consultant in hematology and medical oncology at MRCCC Siloam Semanggi, mutations in these specific genes are directly linked to a substantially elevated lifetime risk of developing not only breast cancer, but also ovarian cancer. Identifying these mutations through advanced molecular diagnostics can provide life-saving insights for patients and their healthcare providers. However, Dr. Jeffry stresses that the decision to pursue such screening must be approached methodically, driven by clinical necessity rather than mere curiosity.
Understanding the Clinical Value of Genetic Screening
Genetic testing for breast and ovarian cancer predisposition is not a routine blood test to be ordered casually. It is a specialized diagnostic procedure designed to detect harmful alterations in DNA sequences that normally function to suppress tumor growth. When these tumor-suppressor genes mutate, they lose their ability to repair damaged DNA, thereby increasing the likelihood that abnormal cells will multiply uncontrollably and form malignant tumors.
For individuals with a strong lineage of malignancy, genetic counseling and subsequent testing can serve as a powerful preventive tool. Knowing one’s mutation status allows patients to adopt enhanced surveillance strategies, such as more frequent mammograms, breast magnetic resonance imaging (MRI), and clinical breast examinations starting at an earlier age. In some high-risk scenarios, individuals who test positive for BRCA mutations may discuss risk-reducing options with their surgical oncologists, ranging from targeted chemoprevention medications to prophylactic surgeries.
Nevertheless, the medical community maintains that these interventions must be tailored to the individual. A blanket approach to genetic screening is neither clinically sound nor economically practical. Healthcare providers must evaluate each patient on a case-by-case basis, carefully mapping out family trees to identify patterns of cancer diagnosis that strongly suggest a hereditary syndrome, such as Hereditary Breast and Ovarian Cancer (HBOC) syndrome.
The Importance of Family Medical History
Establishing a comprehensive family medical history is the foundational step in assessing hereditary cancer risks. Oncologists look for specific red flags when evaluating a patient’s pedigree. These warning signs include multiple family members diagnosed with breast or ovarian cancer, particularly if the diagnoses occurred at a relatively young age—typically under the art of 50. Furthermore, the presence of male breast cancer within a family, bilateral breast cancer in a single individual, or a combination of breast, ovarian, pancreatic, and aggressive prostate cancers across generations often points toward an inherited genetic predisposition.
When such patterns emerge, physicians are far more likely to recommend formal genetic counseling. This specialized branch of medicine involves genetic counselors or trained oncologists who review the family pedigree, estimate the mathematical probability of carrying a harmful mutation, and discuss the implications of testing for both the patient and their broader family network.
The Psychological and Practical Consequences of Test Results
One of the primary reasons medical professionals caution against indiscriminate testing is the psychological weight that accompanies the results. A genetic test does not simply yield a binary answer of healthy or sick; it provides a probability assessment that can drastically alter a person’s worldview.
Receiving a positive result—confirming the presence of a BRCA1 or BRCA2 mutation—can trigger significant anxiety, depression, and chronic distress. Patients often grapple with the fear of developing cancer, the guilt of potentially passing the mutated gene to their children, and the difficult burden of deciding among various risk-reduction strategies. Conversely, a negative result in the context of a strong family history can sometimes lead to survivor guilt or a false sense of security if other unidentified genes are still at play.
Moreover, unexpected or ambiguous results, known as variants of uncertain significance (VUS), can create prolonged periods of diagnostic limbo. A VUS occurs when a genetic alteration is identified, but insufficient scientific data exists at the time of the test to determine whether the specific variant is benign or pathogenic. This leaves patients and physicians uncertain about how to proceed, occasionally causing unnecessary anxiety.
Beyond the psychological dimension, practical concerns regarding genetic testing include issues related to medical privacy, potential discrimination in life or health insurance markets, and the out-of-pocket costs associated with specialized molecular diagnostics. While regulatory frameworks in many jurisdictions offer protections against genetic discrimination, patients must remain informed about their rights and the confidentiality policies of diagnostic laboratories.
Navigating the Decision-Making Process
To ensure that genetic testing serves its intended purpose—improving patient outcomes through early detection and risk mitigation—the medical establishment advocates for a structured pre-test and post-test counseling framework. Patients are strongly discouraged from ordering direct-to-consumer genetic kits without professional medical supervision, as these commercial platforms often provide limited panels, lack contextual interpretation, and fail to offer the critical psychological support required when managing complex hereditary risks.
Instead, individuals who suspect they may be at elevated risk due to family history should initiate a dialogue with their primary care physicians, gynecologists, or dedicated oncologists. These healthcare professionals can provide appropriate referrals to certified genetic counselors who are equipped to explain the nuances of hereditary cancer syndromes.
As precision medicine continues to evolve, the ability to decode our genetic blueprint offers unprecedented opportunities for proactive healthcare. However, as experts like Dr. Jeffry Beta Tenggara remind the public, advanced diagnostics must always be paired with clinical wisdom, informed consent, and emotional preparedness. By treating genetic testing as a serious medical intervention rather than a casual wellness check, individuals can harness the power of science to protect their health while safeguarding their peace of mind.
